2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 911

Neutralization Of Anti-Citrullinated Protein Antibodies – a Way To Go?
Abstract Number: 273

Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk In Patients With Systemic Juvenile Idiopathic Arthritis
Abstract Number: 550

Neutrophil Gelatinase Associated Lipocalin (NGAL/Lipocalin-2) Regulates the Onset Of Serum Autoantibodies In Pristane Induced Lupus
Abstract Number: 636

Neutrophil-Mediated Interferon Activation In Systemic Lupus Erythematosus Bone Marrow
Abstract Number: 1105

New and Not Improved? The Efficacy Of FMS Medications
Abstract Number: 84

New Formulation With Potential To Prevent and Treat Osteoporosis and Osteoarthritis
Abstract Number: 165

New Insights Into The Metabolic Origin Of Osteoarthritis
Abstract Number: 2613

NF-κB Pathway Is Depleted In Phagocytes From Behçet´s Disease Patients Secondarily To Constitutive Phosphorylation Of The p65 Subunit
Abstract Number: 709

Nilotinib (Tasigna™) In The Treatment Of Early Diffuse Systemic Sclerosis: A Single Group, Open Label Pilot Clinical Trial – One Year Results
Abstract Number: 2566

Nilotinib Treatment Effect In The Skin As Measured By DNA Microarray In Patients With Diffuse Systemic Sclerosis
Abstract Number: 1358

No Differences In Patient-Reported Outcomes By Methotrexate Dose Among Early Rheumatoid Arthritis Patients Treated Concomitantly With Adalimumab: Results From The Concerto Trial
Abstract Number: 185

No Secular Trends In Real Live Radiographic Progression Of Rheumatoid Arthritis In Recent Year
Abstract Number: 945

Non-Canonical NF-Kappa B Signaling Enhances Angiogenesis In a Novel 3D Spheroid Model Of Rheumatoid Arthritis Synovial Inflammation
Abstract Number: 1041

Non-Differential Reporting Of Myocardial Infarction To a National Observational Drug Safety Study Using Linked Data: Linkage Of The British Society For Rheumatology Biologics Register For Rheumatoid Arthritis and The Myocardial Ischaemia National Audit Project
Abstract Number: 78

Norepinephrine (NE) Inhibits Mesenchymal Stem Cell (MSCs) Chondrogenesis By Accelerating Hypertophy – Relevance For Cartilage Regeneration

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].